Terms: = Prostate cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Diagnosis
855 results:
1. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
2. [Difference between prostate cancer patients' Gleason scores from preoperative biopsy and those from postoperative pathology].
Zhao XD; Liu YH; Hu J; Wang ZH; Jin XX; Ma MF; Zhou YL; Chen YH; Cao J; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 May; 29(5):393-401. PubMed ID: 38602754
[TBL] [Abstract] [Full Text] [Related]
3. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
4. prostate-Specific Antigen Screening and 15-Year prostate cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract] [Full Text] [Related]
5. Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
Modlin IM; Kidd M; Drozdov IA; Boegemann M; Bodei L; Kunikowska J; Malczewska A; Bernemann C; Koduru SV; Rahbar K
Prostate; 2024 Jun; 84(9):850-865. PubMed ID: 38571290
[TBL] [Abstract] [Full Text] [Related]
6. Machine Learning-Based Prediction of Hospitalization During Chemoradiotherapy With Daily Step Counts.
Friesner ID; Feng J; Kalnicki S; Garg M; Ohri N; Hong JC
JAMA Oncol; 2024 May; 10(5):642-647. PubMed ID: 38546697
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict prostate cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract] [Full Text] [Related]
8. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract] [Full Text] [Related]
9. What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National prostate cancer Audit in England.
Morris M; Cook A; Dodkins J; Price D; Waller S; Hassan S; Nathan A; Aggarwal A; Payne HA; Clarke N; van der Meulen J; Nossiter J
BMJ Open; 2024 Feb; 14(2):e078284. PubMed ID: 38418235
[TBL] [Abstract] [Full Text] [Related]
10. Partial gland ablation with high intensity focal ultrasound impact on genito-urinary function and quality of life: our initial experience.
Fugaru I; Bouhadana D; Marcq G; Moryousef J; Rompré-Brodeur A; Meng A; Loutochin O; Loutochin G; Anidjar M; Bladou F; Sanchez-Salas R
Can J Urol; 2024 Feb; 31(1):11784-11792. PubMed ID: 38401258
[TBL] [Abstract] [Full Text] [Related]
11. Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer.
Zhang C; Gao X; Fan B; Guo S; Lyu X; Shi J; Fu Y; Zhang Q; Liu P; Guo H
World J Urol; 2024 Feb; 42(1):93. PubMed ID: 38386116
[TBL] [Abstract] [Full Text] [Related]
12. Medication-based Comorbidity Measures and prostate cancer Treatment Selection.
Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
[TBL] [Abstract] [Full Text] [Related]
13. Association of Medicaid Privatization With Patient cancer Outcomes.
Sunkara PR; Waitzman J; Lenze NR; Brenner MJ; Cramer JD
JCO Oncol Pract; 2024 May; 20(5):708-716. PubMed ID: 38295328
[TBL] [Abstract] [Full Text] [Related]
14. Psychological Distress, Emergency Room Utilization, and Mortality Risk Among US Adults With History of prostate cancer.
Jiang C; Xing J; Sanders A; Chidester K; Shi M; Perimbeti S; Deng L; Chatta GS; Gopalakrishnan D
JCO Oncol Pract; 2024 Apr; 20(4):509-516. PubMed ID: 38290084
[TBL] [Abstract] [Full Text] [Related]
15. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
16. Diagnostic Performance of
Light A; Lazic S; Houghton K; Bayne M; Connor MJ; Tam H; Ahmed HU; Shah TT; Barwick TD
J Nucl Med; 2024 Mar; 65(3):379-385. PubMed ID: 38212074
[TBL] [Abstract] [Full Text] [Related]
17. Differential association between dairy intake patterns and incident prostate cancer: a potential dairy matrix effect.
Armenta-González LL; Hernández-Pérez JG; Feeney EL; Vázquez-Salas A; Galván-Portillo M; López DS; Torres-Sánchez L
Eur J Nutr; 2024 Apr; 63(3):847-857. PubMed ID: 38197912
[TBL] [Abstract] [Full Text] [Related]
18. Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
[TBL] [Abstract] [Full Text] [Related]
19. Performance evaluate of different chemometrics formalisms used for prostate cancer diagnosis by NMR-based metabolomics.
Oliveira MF; de Albuquerque Neto MC; Leite TS; Alves PAA; Lima SVC; Silva RO
Metabolomics; 2023 Dec; 20(1):8. PubMed ID: 38127222
[TBL] [Abstract] [Full Text] [Related]
20. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant prostate cancer in a National Health Care Delivery System.
Nguyen CB; Kobe C; Kumbier KE; Bauman J; Burns JA; Tsao PA; Sparks JB; Skolarus TA; Caram MEV
JCO Oncol Pract; 2024 Jan; 20(1):59-68. PubMed ID: 38085028
[TBL] [Abstract] [Full Text] [Related]
[Next]
